Dr. James L. McCarley, Jr., Chairman and CEO of Cantrell Drug Company, https://cantrelldrug.com/, a 503B Registered Outsourcing Facility, announced that his Company has received final approval from the FDA to begin producing and shipping product under the terms and conditions of a Consent Decree Agreement with the FDA that was signed on April 19th of this year. Click here to view the letter from John W. Diehl, M.S. Director, Compliance Branch of the FDA in Dallas.
Dr. McCarley commented: “Patient safety is Cantrell Drug’s number one priority. Cantrell has been through the most robust of federal and independent reviews. The FDA’s approval means our facilities, equipment, and processes meet current Good Manufacturing Practice standards. We wholeheartedly share the FDA’s objective to ensure our drugs are safe and effective. We are readier than ever before to supply patients with quality medications!”
Dr. McCarley said that Cantrell Drug will resume operations by producing two drugs that are in critically short supply: Morphine Sulfate 2mg/ml Injection Solution 1ml Syringe and Hydromorphone 1mg/ml 1ml fill BD 3ml Syringe.
Cantrell Drug Company, founded in 1962, provides sterile injectable pharmaceuticals that are primarily used in hospital operating room suites and are in short supply.
Dr. McCarley said: “I started my career as a retail pharmacist and I’m keenly aware that behind every batch, every order, every syringe is a patient with a name; someone’s spouse, father, mother, brother, sister, friend or relative. The drugs we make help save lives and for that I’m humbled and I’m grateful to have the opportunity to be of service to our customers, and to their patients. To our customers, and to our vendors and suppliers, thank you for your understanding. Thank you for your patience. And most of all, thank you for your continued business.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20180925005854/en/
Contacts:
Steven Weintz, 843-822-7664
Vice
President
sweintz@cantrelldrug.com
